REGENXBIO receives FDA response for RGX-121 application
REGENXBIO plans to request a Type A meeting with the FDA to discuss the CRL and its planned BLA resubmission.
Drug Development
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
Innovent and Lilly to advance new oncology and immunology medicines
Novartis starts construction on new research facility in San Diego, US
BMS reports flat revenue growth for full-year 2025
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Everest Medicines and Micot partner on MT1013 commercialisation
PrimeGen US and DT Cloud Star sign $1.5bn merger agreement
